Derazil (Canada)This page contains information on Derazil for veterinary use.
The information provided typically includes the following:
- Derazil Indications
- Warnings and cautions for Derazil
- Direction and dosage information for Derazil
DerazilThis treatment applies to the following species:
Transforming Powder Dressing
FOR VETERINARY USE ONLY
DERAZIL™ Transforming Powder Dressing is an innovative product that uses nanoflex technology for dressing exudative wounds such as burns, abrasions, lacerations, surgical wounds, and chronic, slow-healing wounds. DERAZIL is a sterile white powder consisting of nanoflex acrylic polymers that when applied to an exudative wound is transformed into a permeable, flexible barrier that protects wounds from contamination and promotes healing. DERAZIL is packaged in sterile foil-laminate pouches for single applications.
Directions For Use
DERAZIL is indicated for use in:
● Exudative wounds such as abrasions, lacerations and burns
● Surgical wounds, such as post-operative wounds or dermatological excisions (only as a primary dressing over wound, not to be used as replacement for sutures)
● Chronic, slow-healing open wounds
STEP 1. Wound Preparation
Prior to application of DERAZIL, clean the wound area and remove any necrotic tissue that may be present. Clip hair surrounding the wound to prevent contamination and promote adhesion of the dressing. Ensure that the wound area is moist and free of oil-based products e.g. wound pastes, ointments, etc. Activation of DERAZIL requires sufficient moisture to activate the powder to form the dressing. Apply additional sterile saline to the wound if needed.
STEP 2. Application of DERAZIL
Apply DERAZIL evenly over the entire surface of the wound. Use sterile technique to spread product to form a thin uniform layer over the entire surface up to the skin edges of the wound. Allow the powder to absorb the moisture from the wound to form the dressing. The formation of the dressing will take approximately between 30 seconds and 3 minutes depending on the level of exudate. The formation of the dressing can be accelerated with the application of sterile saline sparingly to the powder on the wound. If unactivated powder remains and a uniform dressing layer is not formed within a few minutes after application, gently mist the powder with sterile saline. The powder may still appear white and granular; however, the intact dressing will gradually form. The colouration of the powder can change depending on the level of blood or exudate within the wound. The final appearance of the dressing is a translucent film that covers the wound. More powder can be applied to areas of the wound if needed.
DERAZIL does not provide complete protection against infection and can be used in conjunction with other infection control protection measures. Topical oil-based antibiotics are not recommended for use with DERAZIL as they may interfere with DERAZIL aggregation.
STEP 3. Post-Application and Dressing Care
Avoid getting the dressing wet.
Secondary dressings following application of DERAZIL can be used. Bandaging material used as part of a secondary dressing should be vapour permeable to allow vapour exchange and should not include any oil-based product that may interfere with aggregation of DERAZIL.
All wounds should be inspected regularly following application of DERAZIL. If infection, inflammation, excessive bleeding, excessive fluid or irritation occurs, remove the dressing by saturating with sterile saline for 3 to 5 minutes, then gently lift the edges of the dressing from the wound.
If proudflesh appears during the healing process, debridement of that tissue with further application of DERAZIL is recommended.
STEP 4. Removal of DERAZIL
DERAZIL remains in contact with the wound surface until a layer of skin forms underneath and the wound no longer produces an exudate. Areas of the dressing will flake off as skin forms over the wound. If DERAZIL remains intact at 14 days following application, thoroughly saturate with sterile saline and remove by gently lifting the dressing, starting at the edges. Replace as deemed necessary.
DERAZIL is not for use in non-exudative wounds and should not be used in animals with known sensitivity or allergic reaction to the dressing.
Avoid the use of oil-based topical products, as they can interfere with DERAZIL aggregation.
Risk of Aspiration
Since DERAZIL is a powder, should there be a concern to avoid nuisance dust, health care professionals with respiratory problems or asthma should wear a dust mask approved under appropriate government standards such as type N95 (US) or type P1 (EN143) to avoid inhalation of particles.
Keep out of the reach of children.
Store at room temperature.
DERAZIL Transforming Powder Dressing is supplied in foil-laminate pouches each containing 5 grams of powder to cover approximately 25 cm x 25 cm.
This product is for single use only. Discard any unused portion of the product. Do not use if pouch is opened or damaged.
Packaging consists of an outer box which contains 5 foil-laminate pouches.
For additional information and support, please call the toll-free Novartis Animal Health customer service line at 1-800-387-6325.
Manufactured by Uluru Inc., 4452 Beltway Drive, Addison, TX 75001 USA
Distributed by Novartis Animal Health Canada Inc., 2233 Argentia Road, Suite 205, Mississauga, Ontario, L5N 2X7, Canada
DERAZIL is a trademark of Novartis AG, used under license.
609287 CAN 310044
NAC No.: 1231115.0
Distributed by ELANCO, Division Eli Lilly Canada Inc. & ELANCO CANADA LIMITED (successor to Novartis Animal Health Canada Inc.)
RESEARCH PARK CENTRE, 150 RESEARCH LANE, SUITE 120, GUELPH, ON, N1G 4T2
|Elanco Canada Limited Customer Service Telephone:||800-387-6325|
|Elanco Canada Limited Customer Service Fax:||800-827-5782|
|Every effort has been made to ensure the accuracy of the Derazil information published above. However, it remains the responsibility of the readers to familiarize themselves with the product information contained on the Canadian product label or package insert.|
Copyright © 2016 North American Compendiums. Updated: 2016-08-21